Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an investigational neonatal Fc receptor (FcRn) blocker, in ...

Leveraging the full potential of FcRn-pH-HPLC enables Affimed an early selection of innate cell engagers (ICE ®) with tailored pharmacokinetic (PK) profiles and to thereby develop drug candidates ...

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2017 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today an ...

Researchers assessed the SARS-CoV-2 variants of concern (VOCs) transmission dynamics and neutralization by vaccine-induced antibodies and monoclonal antibodies (mAbs).

--Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’ s and other neurodegenerative diseases through the inhibition of SEMA4D ...

Monoclonal antibodies (mAbs) can achieve unparalleled affinity and specificity for a wide range of biomolecules, making the reagents critical to both basic and clinical research. The vast majority ...

a. mAbs is a multidisciplinary, peer-reviewed, open access journal dedicated to the art and science of antibody research and development. b. Dr. Pushpa Narayanaswami has provided consulting ...